What are the Historical Developments and Current Growth Metrics of the Onpattro Market?
The onpattro market has seen considerable growth due to a variety of factors.
• Recent years have seen the onpattro market size achieve XX (HCAGR). The market, which is projected to expand from $XX million in 2024 to $XX million in 2025, displaying a compound annual growth rate (CAGR) of XX%, owes its growth in the historical period to several factors.
These include an increase in hereditary transthyretin-mediated amyloidosis cases, greater awareness of uncommon diseases, an uptick in research and development investments, an aging population segment, and an upsurge in healthcare spending.
What Does Future Hold for The Onpattro Market By 2029?
The onpattro market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market size for onpattro is predicted to experience a XX (FCAGR) increase. By 2029, it's projected that the market will be valued at $XX million, growing at a compound annual growth rate (CAGR) of XX%.
The growth witnessed during the forecast period can be credited to factors like collaborations, licensing, regulatory backing, growing incidence of chronic diseases, burgeoning collaborations within the biopharmaceutical industry, and rising cases of transthyretin amyloidosis. Major trends to note during the forecast period include increasing use of ribonucleic acid-based therapies, a surge in orphan drug designations, integration of digital healthcare tools, a shift to personalized medicine, and technological progress in drug delivery.
What Are The Primary Growth Drivers In The Onpattro Market?
The increasing occurrence of hereditary transthyretin-mediated amyloidosis is anticipated to stimulate the expansion of the onpattro market. This uncommon genetic disorder, often referred to as hATTR, involves the formation of harmful deposits from mutated TTR proteins, which adversely impact the nerves and heart. Improved diagnostic techniques, genetic testing, and heightened awareness have contributed to the escalating prevalence of hATTR, leading to the identification of more cases. Onpattro is utilized in the treatment of hATTR, where it works by silencing the TTR gene in order to decrease the production of amyloid protein and thereby hinder organ damage. For instance, data from Verywell Health, a health information business based in the US, indicated that in February 2024, hATTR impacted between 5,500 and 38,500 individuals globally, with US estimates suggestive of 104 to 3,847 cases of hATTR with polyneuropathy. This points to a considerable underdiagnosis. Therefore, the escalating occurrence of hATTR is fueling the expansion of the onpattro market.
What Is The Segmentation Of The Global Onpattro Market?
The onpattro market covered in this report is segmented –
1) By Clinical Indication: Hereditary Transthyretin-Mediated Amyloidosis, Wild-Type Transthyretin Amyloidosis, Other Transthyretin-Related Amyloidoses
2) By Distribution Channel: Direct Sales, Pharmacies, Online Pharmacies
3) By End User: Hospitals, Specialty Clinics, Home Healthcare Providers
Pre-Book The Onpattro Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Onpattro Market?
One notable trend in the Onpattro market involves extending the potential uses of the drug with supplemental drug applications to cater to a broader range of patient requirements and maximize market yield. This typically involves expanding the drug's approved applications to include new indications, populations, or formulations, in order to widen its medicinal scope and potential market reach. For example, Alnylam Pharmaceuticals, a pharmaceutical company based in the US, announced in February 2023 that it had secured acceptance for a Supplemental New Drug Application (sNDA) for ONPATTRO (patisiran), a treatment aimed at cardiomyopathy associated with transthyretin amyloidosis (ATTR). ONPATTRO is a therapeutic RNA interference (RNAi) drug designed to uniquely target the transthyretin (TTR) protein, which can excessively build up in patients suffering from ATTR amyloidosis, leading to serious complications like cardiomyopathy. The initial approval of the drug in 2018 was for the treatment of polyneuropathy in relation to inherited ATTR amyloidosis. The latest sNDA proposal was grounded on findings from the Phase III APOLLO-B study, which showed that patisiran notably enhanced the functional capacity and life quality in patients with cardiomyopathy compared to a placebo.
Who Are the Key Players In The Onpattro Market?
Major companies operating in the onpattro market include:
• Alnylam Pharmaceuticals Inc.
What Are The Regional Insights Into The Onpattro Market?
North America was the largest region in the onpattro market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onpattro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
